A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation

Bimal R. Shah, Eva Scholtus, Catherine Rolland, Ariane Batscheider, Jason N. Katz, Kent R Nilsson

Research output: Contribution to journalArticle

Abstract

Objective: Non-valvular atrial fibrillation (NVAF), a common cardiac arrhythmia, is associated with high morbidity and carries a substantial economic burden. Historically, vitamin K antagonists (VKAs; e.g. warfarin) have been used for therapy of NVAF, but recently several direct oral anticoagulants (DOACs) have been approved for prevention of stroke in patients with NVAF. This review summarizes the real-world evidence (RWE) for healthcare resource utilization (HRU) in patients receiving oral anticoagulants (VKAs and/or DOACs) for therapy of NVAF. Methods: A PRISMA-compliant literature search assessed Medline ® and Embase ® databases from 1 January 2011 to 4 May 2017, and the National Health Service Economic Evaluation Database from 1 January 2011 to 31 December 2015. Publications were included if they reported observational data from real-world use of one or more anticoagulant therapies. Outcomes of interest included hospitalizations, length of stay (LOS), mortality and costs. Results: Twenty-eight publications were included. Apixaban and dabigatran were associated with fewer bleed-related hospitalizations than warfarin. Bleed-related LOS were generally longer for warfarin than for DOACs. Bleed-related treatment costs were lower for patients receiving apixaban or receiving dabigatran than patients receiving rivaroxaban or receiving warfarin. Bleed-related mortality in patients receiving oral anticoagulation for treatment of NVAF were low across all DOACs and warfarin. Conclusions: The limited available evidence for HRU burden among patients receiving oral anticoagulation for NVAF suggests that DOACs (particularly apixaban and dabigatran) offer some degree of benefit in terms of HRU outcomes, compared with warfarin. Further work is required to understand HRU outcomes in patients receiving DOACs.

Original languageEnglish (US)
Pages (from-to)127-139
Number of pages13
JournalCurrent Medical Research and Opinion
Volume35
Issue number1
DOIs
StatePublished - Jan 2 2019

Fingerprint

Anticoagulants
Atrial Fibrillation
Publications
Warfarin
Delivery of Health Care
Length of Stay
Hospitalization
Databases
Vitamin K
Mortality
Health Services Research
National Health Programs
Therapeutics
Health Care Costs
Cost-Benefit Analysis
Cardiac Arrhythmias
Stroke
Economics
Morbidity
Costs and Cost Analysis

Keywords

  • apixaban
  • dabigatran
  • edoxaban
  • healthcare resource utilization
  • hemorrhage
  • non-valvular atrial fibrillation
  • rivaroxaban

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation. / Shah, Bimal R.; Scholtus, Eva; Rolland, Catherine; Batscheider, Ariane; Katz, Jason N.; Nilsson, Kent R.

In: Current Medical Research and Opinion, Vol. 35, No. 1, 02.01.2019, p. 127-139.

Research output: Contribution to journalArticle

@article{352ea3448ead4e7cb80520d5ec7259d3,
title = "A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation",
abstract = "Objective: Non-valvular atrial fibrillation (NVAF), a common cardiac arrhythmia, is associated with high morbidity and carries a substantial economic burden. Historically, vitamin K antagonists (VKAs; e.g. warfarin) have been used for therapy of NVAF, but recently several direct oral anticoagulants (DOACs) have been approved for prevention of stroke in patients with NVAF. This review summarizes the real-world evidence (RWE) for healthcare resource utilization (HRU) in patients receiving oral anticoagulants (VKAs and/or DOACs) for therapy of NVAF. Methods: A PRISMA-compliant literature search assessed Medline {\circledR} and Embase {\circledR} databases from 1 January 2011 to 4 May 2017, and the National Health Service Economic Evaluation Database from 1 January 2011 to 31 December 2015. Publications were included if they reported observational data from real-world use of one or more anticoagulant therapies. Outcomes of interest included hospitalizations, length of stay (LOS), mortality and costs. Results: Twenty-eight publications were included. Apixaban and dabigatran were associated with fewer bleed-related hospitalizations than warfarin. Bleed-related LOS were generally longer for warfarin than for DOACs. Bleed-related treatment costs were lower for patients receiving apixaban or receiving dabigatran than patients receiving rivaroxaban or receiving warfarin. Bleed-related mortality in patients receiving oral anticoagulation for treatment of NVAF were low across all DOACs and warfarin. Conclusions: The limited available evidence for HRU burden among patients receiving oral anticoagulation for NVAF suggests that DOACs (particularly apixaban and dabigatran) offer some degree of benefit in terms of HRU outcomes, compared with warfarin. Further work is required to understand HRU outcomes in patients receiving DOACs.",
keywords = "apixaban, dabigatran, edoxaban, healthcare resource utilization, hemorrhage, non-valvular atrial fibrillation, rivaroxaban",
author = "Shah, {Bimal R.} and Eva Scholtus and Catherine Rolland and Ariane Batscheider and Katz, {Jason N.} and Nilsson, {Kent R}",
year = "2019",
month = "1",
day = "2",
doi = "10.1080/03007995.2018.1543184",
language = "English (US)",
volume = "35",
pages = "127--139",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation

AU - Shah, Bimal R.

AU - Scholtus, Eva

AU - Rolland, Catherine

AU - Batscheider, Ariane

AU - Katz, Jason N.

AU - Nilsson, Kent R

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Objective: Non-valvular atrial fibrillation (NVAF), a common cardiac arrhythmia, is associated with high morbidity and carries a substantial economic burden. Historically, vitamin K antagonists (VKAs; e.g. warfarin) have been used for therapy of NVAF, but recently several direct oral anticoagulants (DOACs) have been approved for prevention of stroke in patients with NVAF. This review summarizes the real-world evidence (RWE) for healthcare resource utilization (HRU) in patients receiving oral anticoagulants (VKAs and/or DOACs) for therapy of NVAF. Methods: A PRISMA-compliant literature search assessed Medline ® and Embase ® databases from 1 January 2011 to 4 May 2017, and the National Health Service Economic Evaluation Database from 1 January 2011 to 31 December 2015. Publications were included if they reported observational data from real-world use of one or more anticoagulant therapies. Outcomes of interest included hospitalizations, length of stay (LOS), mortality and costs. Results: Twenty-eight publications were included. Apixaban and dabigatran were associated with fewer bleed-related hospitalizations than warfarin. Bleed-related LOS were generally longer for warfarin than for DOACs. Bleed-related treatment costs were lower for patients receiving apixaban or receiving dabigatran than patients receiving rivaroxaban or receiving warfarin. Bleed-related mortality in patients receiving oral anticoagulation for treatment of NVAF were low across all DOACs and warfarin. Conclusions: The limited available evidence for HRU burden among patients receiving oral anticoagulation for NVAF suggests that DOACs (particularly apixaban and dabigatran) offer some degree of benefit in terms of HRU outcomes, compared with warfarin. Further work is required to understand HRU outcomes in patients receiving DOACs.

AB - Objective: Non-valvular atrial fibrillation (NVAF), a common cardiac arrhythmia, is associated with high morbidity and carries a substantial economic burden. Historically, vitamin K antagonists (VKAs; e.g. warfarin) have been used for therapy of NVAF, but recently several direct oral anticoagulants (DOACs) have been approved for prevention of stroke in patients with NVAF. This review summarizes the real-world evidence (RWE) for healthcare resource utilization (HRU) in patients receiving oral anticoagulants (VKAs and/or DOACs) for therapy of NVAF. Methods: A PRISMA-compliant literature search assessed Medline ® and Embase ® databases from 1 January 2011 to 4 May 2017, and the National Health Service Economic Evaluation Database from 1 January 2011 to 31 December 2015. Publications were included if they reported observational data from real-world use of one or more anticoagulant therapies. Outcomes of interest included hospitalizations, length of stay (LOS), mortality and costs. Results: Twenty-eight publications were included. Apixaban and dabigatran were associated with fewer bleed-related hospitalizations than warfarin. Bleed-related LOS were generally longer for warfarin than for DOACs. Bleed-related treatment costs were lower for patients receiving apixaban or receiving dabigatran than patients receiving rivaroxaban or receiving warfarin. Bleed-related mortality in patients receiving oral anticoagulation for treatment of NVAF were low across all DOACs and warfarin. Conclusions: The limited available evidence for HRU burden among patients receiving oral anticoagulation for NVAF suggests that DOACs (particularly apixaban and dabigatran) offer some degree of benefit in terms of HRU outcomes, compared with warfarin. Further work is required to understand HRU outcomes in patients receiving DOACs.

KW - apixaban

KW - dabigatran

KW - edoxaban

KW - healthcare resource utilization

KW - hemorrhage

KW - non-valvular atrial fibrillation

KW - rivaroxaban

UR - http://www.scopus.com/inward/record.url?scp=85058167298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058167298&partnerID=8YFLogxK

U2 - 10.1080/03007995.2018.1543184

DO - 10.1080/03007995.2018.1543184

M3 - Article

VL - 35

SP - 127

EP - 139

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 1

ER -